Passage BIO, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Cash from operations | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Capital expenditure | — | $34,000 | — | — | — |
| Free cash flow | — | -$48.0M | — | — | — |
| Impairments | $6.1M | $5.2M | $5.4M | $0 | $0 |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
Shares outstanding 3.2M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.